Kabi Introduces Idacio Into Crowded German Adalimumab Market
Executive Summary
Fresenius Kabi is entering a German adalimumab market in which Amgen, Mylan and Sandoz are already competing against AbbVie’s Humira reference brand. In this environment, Fresenius’ sales expectations are modest.
You may also be interested in...
The EU's Top Valsartan Lesson: Closely Examine Active Substance Manufacturing Processes
EU report on “lessons learnt” from the valsartan crisis calls for tighter GMP controls on API suppliers.
Kabi Commits To Biosimilars Development
Fresenius Kabi says a research and development center that it has opened in Switzerland demonstrates its commitment to its biosimilars pipeline.
Fresenius Tempers Expectations For Adalimumab Biosimilar
As a late entrant to the European adalimumab market, Fresenius is cooling expectations for sales of its Idacio biosimilar while it continues work on late-stage candidates pegfilgrastim and tocilizumab.